This result, and subsequent preclinical studies, fostered the idea that the releasing of the “brakes” of the immune system could increase anti-tumor immunity, thus paving the way for the clinical development of CTLA-4 antibodies and starting the new era of immune checkpoint therapy. The gene discussed is CTLA4; the disease is neoplasm.